

Eun Ji Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10033014/publications.pdf>

Version: 2024-02-01

9
papers

41
citations

1937685
4
h-index

1872680
6
g-index

9
all docs

9
docs citations

9
times ranked

27
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 153, 179-189.	2.8	16
2	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. <i>Yonsei Medical Journal</i> , 2022, 63, 42.	2.2	7
3	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. <i>Frontiers in Oncology</i> , 2022, 12, 821391.	2.8	6
4	SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. <i>Clinical and Translational Immunology</i> , 2022, 11, e1364.	3.8	6
5	Abstract 1826: Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeutic antibody candidate with bispecific immuno-oncology target. <i>Cancer Research</i> , 2021, 81, 1826-1826.	0.9	5
6	Abstract LB515A: A MET targeting biparatopic antibody-drug conjugates (ADC), REGN5093-M114, has an antitumor efficacy in NSCLC harboring MET gene alterations. <i>Cancer Research</i> , 2022, 82, LB515A-LB515A.	0.9	1
7	572...Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TME... potentiates anti-cancer effects in preclinical cancer models. , 2020, , .		0
8	Abstract 5481: Combination therapy with anti-PD-1 and YH29407, a novel IDO1 inhibitor, enhances T cell-mediated antitumor immunity in MC38 tumor-bearing mice. <i>Cancer Research</i> , 2022, 82, 5481-5481.	0.9	0
9	Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs. <i>Cancer Research</i> , 2022, 82, LB544-LB544.	0.9	0